Overcoming why a new treatment is resisted by lung cancer

July 29, 2015

A promising agent for the treatment of cancer has so far had little effect on the most common lung tumours, but new research from The University of Manchester has suggested how this resistance might be overcome.

In two papers released in the journal PNAS, the research team examined factors which mean that the most common type of lung cancer - itself the most common cause of cancer deaths - is resistant to a cytokine called TRAIL that causes cell death in many other types of tumour.

The researchers found that in non-small cell lung cancer, which accounts for around 85 percent of cases, a small RNA molecule called miR-148a is suppressed in TRAIL resistant cells, but that when used together, miR-148a sensitises tumour cells to TRAIL and results in the tumour shrinking.

Dr Michela Garofalo, from the CRUK Manchester Institute led the research. She said: "Discovering a potential reason why TRAIL is resisted by lung cancer could lead us to new treatments for this particularly deadly form of the disease.

"miR-148a certainly seems to play a role in this resistance, so it's an avenue to explore alongside other factors which influence how the tumours respond to treatment."

In related research also published in PNAS, Dr Garofalo's team discovered another mechanism which makes tumours resistant to TRAIL. NF-κB is a protein which TRAIL itself increases the supply of in resistant lung tumours. By supressing it in cells they found that TRAIL became much more effective at causing tumour cells to die.

"TRAIL is currently in clinical trials for other cancer types," added Dr Garofalo. "But little is known about why non-small cell lung cancer is so resistant. These findings begin to shed light on those unique reasons, and suggest that by inhibiting the factors that cause resistance, TRAIL might become a useful treatment."

University of Manchester

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.